Cardinal Health (NYSE:CAH) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Cardinal Health to reach your target.
Based on historical returns, we believe that Cardinal Health can grow its free cash at a rate of about 16%. That's positive!
| Advantages | Disadvantages |
|---|---|
|
|
| CAH Price (Cardinal Health stock price per share) |
$272.81 | |
|
|
CAH Fair Price (based on intrinsic value) |
$417.54 |
| CAH Safety Price (based on a variable margin of safety) | $334.03 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 17% lower than other Unknown stocks | |
| PE Ratio versus Industry | 26% lower than other Unknown stocks | |
| Cash Yield | 4.27% | |
| Free Cash Flow Jitter | 32% | |
| Dividend Yield | 0.75% (tax impact) | Shares Shorted | 7,577,324 |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 7,577,324 shares shorted. With 230,681,316 shares available for purchase and an average trading volume over the past 10 trading days of 1,549,320, it would take at least 4.9 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2008 | 721371 | 1,542 |
| 2009 | 721371 | 1,213 |
| 2010 | 721371 | 1,907 |
| 2011 | 721371 | 1,152 |
| 2012 | 721371 | 930 |
| 2013 | 721371 | 1,442 |
| 2014 | 721371 | 2,273 |
| 2015 | 721371 | 2,281 |
| 2016 | 721371 | 2,677 |
| 2017 | 721371 | 865 |
| 2018 | 721371 | 2,411 |
| 2019 | 721371 | 2,349 |
| 2020 | 721371 | 1,572 |
| 2021 | 721371 | 2,054 |
| 2022 | 721371 | 2,800 |
| 2023 | 721371 | 2,450 |
| 2024 | 721371 | 3,331 |
| 2025 | 721371 | 1,932 |
| 2026 | 721371 | 4,659 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 17 fiscal years from 2008 to 2026 with positive net income, operating cash flow totaled $40,713 million against net income of $17,239 million, or 2.36 times. Net income was negative in 2 of the 19 years, and those years are left out of the ratio.
In 2026, operating cash flow was 3.02 times net income, compared with 1.65 times for the earliest three years (2008 to 2010).
In 2026, capital expenditures were $649 million, 12.5% of operating cash flow of $5,174 million, which leaves an estimated $4,525 million after capex. Across the 18 years with reported capex, it averaged 15.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2008 | 1,301 | 1,542 | not reported | 1.19 |
| 2009 | 1,152 | 1,424 | 421 | 1.24 |
| 2010 | 642 | 2,134 | 260 | 3.32 |
| 2011 | 959 | 1,395 | 291 | 1.45 |
| 2012 | 1,069 | 1,176 | 260 | 1.10 |
| 2013 | 334 | 1,727 | 195 | 5.17 |
| 2014 | 1,166 | 2,524 | 249 | 2.16 |
| 2015 | 1,215 | 2,540 | 300 | 2.09 |
| 2016 | 1,427 | 2,971 | 465 | 2.08 |
| 2017 | 1,288 | 1,184 | 387 | 0.92 |
| 2018 | 256 | 2,768 | 384 | 10.81 |
| 2019 | 1,363 | 2,722 | 328 | 2.00 |
| 2020 | -3,696 | 1,960 | 375 | n/a |
| 2021 | 611 | 2,429 | 400 | 3.98 |
| 2022 | -938 | 3,175 | 387 | n/a |
| 2023 | 330 | 2,844 | 481 | 8.62 |
| 2024 | 852 | 3,762 | 511 | 4.42 |
| 2025 | 1,561 | 2,397 | 547 | 1.54 |
| 2026 | 1,714 | 5,174 | 649 | 3.02 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 10 fiscal years from 2017 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $24,423 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 10 of those years with dividend payment facts, dividends paid totaled $5,445 million, 22.3% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.
In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $8,173 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2026, dividends and cash spent repurchasing shares together were $1,849 million, 39.7% of estimated free cash flow of $4,659 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2017 | 865 | 577 | 600 | 1,177 | 136.1% |
| 2018 | 2,411 | 581 | 550 | 1,131 | 46.9% |
| 2019 | 2,349 | 577 | 600 | 1,177 | 50.1% |
| 2020 | 1,572 | 569 | 350 | 919 | 58.5% |
| 2021 | 2,054 | 573 | 200 | 773 | 37.6% |
| 2022 | 2,800 | 559 | 1,000 | 1,559 | 55.7% |
| 2023 | 2,450 | 525 | 2,000 | 2,525 | 103.1% |
| 2024 | 3,331 | 499 | 750 | 1,249 | 37.5% |
| 2025 | 1,932 | 494 | 765 | 1,259 | 65.2% |
| 2026 | 4,659 | 491 | 1,358 | 1,849 | 39.7% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $87,408 million in 2008 and $254,248 million in 2026, a compound annual growth rate of 6.1% over 18 years.
Revenue rose 14.2% from 2025 to 2026.
Our estimated free cash flow was $4,659 million in 2026, 1.8% of revenue. In 2008 the estimated margin was 1.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2008 | 87,408 | 1,542 | 1.8% |
| 2009 | 95,992 | 1,213 | 1.3% |
| 2010 | 98,503 | 1,907 | 1.9% |
| 2011 | 102,644 | 1,152 | 1.1% |
| 2012 | 107,552 | 930 | 0.9% |
| 2013 | 101,093 | 1,442 | 1.4% |
| 2014 | 91,084 | 2,273 | 2.5% |
| 2015 | 102,531 | 2,281 | 2.2% |
| 2016 | 121,546 | 2,677 | 2.2% |
| 2017 | 129,976 | 865 | 0.7% |
| 2018 | 136,809 | 2,411 | 1.8% |
| 2019 | 145,534 | 2,349 | 1.6% |
| 2020 | 152,922 | 1,572 | 1.0% |
| 2021 | 162,467 | 2,054 | 1.3% |
| 2022 | 181,326 | 2,800 | 1.5% |
| 2023 | 204,979 | 2,450 | 1.2% |
| 2024 | 226,827 | 3,331 | 1.5% |
| 2025 | 222,578 | 1,932 | 0.9% |
| 2026 | 254,248 | 4,659 | 1.8% |
How to read this: how debt and assets are compared, the current ratio.
In 2026, cash and equivalents were $4,856 million against total liabilities of $60,023 million, or 8.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 104.8% of total assets in 2026, compared with 65.3% in 2009, an increase of 39.5 percentage points.
Stockholders equity was negative in 2026, at -$2,724 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 54.6% in 2026. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2009 | 25,119 | 1,221 | 16,394 | 8,725 |
| 2010 | 19,990 | 2,755 | 14,714 | 5,276 |
| 2011 | 22,846 | 1,929 | 16,997 | 5,849 |
| 2012 | 24,260 | 2,274 | 18,016 | 6,244 |
| 2013 | 25,819 | 1,901 | 19,844 | 5,975 |
| 2014 | 26,033 | 2,865 | 19,632 | 6,401 |
| 2015 | 30,142 | 4,616 | 23,886 | 6,256 |
| 2016 | 34,122 | 2,356 | 27,434 | 6,571 |
| 2017 | 40,112 | 6,879 | 33,166 | 6,828 |
| 2018 | 39,951 | 1,763 | 33,880 | 6,059 |
| 2019 | 40,963 | 2,531 | 34,633 | 6,330 |
| 2020 | 40,766 | 2,771 | 38,974 | 1,792 |
| 2021 | 44,453 | 3,407 | 42,830 | 1,794 |
| 2022 | 43,878 | 4,717 | 44,760 | -706 |
| 2023 | 43,349 | 4,076 | 46,306 | -2,957 |
| 2024 | 45,121 | 5,133 | 48,333 | -3,212 |
| 2025 | 53,122 | 3,874 | 55,756 | -2,634 |
| 2026 | 57,299 | 4,856 | 60,023 | -2,724 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $272.81, our model's value equals that price if free cash flow grows an average of 10.5 percent a year over the 10 projection years. Our model assumes 16.1 percent a year for this stock, so the price implies growth of 10.5 percent, which is below the 16.1 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $2,691 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $218.25 | 7.7% |
| Current price | $272.81 | 10.5% |
| 20 percent above the current price | $327.37 | 12.9% |
| Our model (stored fair price) | $417.54 | 16.1% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
Every one of the 19 fiscal years we have for Cardinal Health under its current filer shows positive free cash flow.
Free cash flow from the first three years of data averaged $1,554 million, and from the last three $3,307 million: a sharp rise.
Free cash flow is uneven from year to year, with a variability measure of 32%.
At $272.81, Cardinal Health trades below our safe value estimate of $334.03 and our fair value estimate of $417.54.
The dividend yield for Cardinal Health is 0.75%.
Our value investing guide explains how to test these numbers against the filings themselves.
Every fiscal year on this page is reported by one SEC filer, CIK 721371.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: CAH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Cardinal Health have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to CAH: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market